Literature DB >> 7859792

CD3-negative lymphoproliferative disease of granular lymphocytes in a girl with an unusual pattern of anti-Epstein-Barr virus antibodies.

Y Fukunaga1, T Asano, J Takehana, K Ambo, K Matsuoka, M Yamamoto.   

Abstract

UNLABELLED: We describe an 11-year-old girl who initially had mild hepatosplenomegaly and then presented with abnormal expansion of CD3-negative granular lymphocytes in peripheral blood and Epstein-Barr virus (EBV) genome in the DNA obtained from the peripheral blood mononuclear cells (PBMNC). After approximately 3 years, she developed oedema, ascites, marked hepatosplenomegaly, and pancytopenia, and showed both a profile of anti-EBV antibodies of reactivated infection and a high titre of anti-cytomegalovirus antibody. Although she was treated with antibiotics, ganciclovir, and prednisolone, she died of hepatic failure.
CONCLUSION: Careful clinical observation, periodic examination of anti-EBV antibodies, and the analysis of EBV genome from PBMNC are needed in young patients with CD3-negative lymphoproliferative disease of granular lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859792     DOI: 10.1007/bf01954741

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  8 in total

Review 1.  Granular lymphocyte proliferative disorders: report of 12 cases and review of the literature.

Authors:  K Oshimi
Journal:  Leukemia       Date:  1988-10       Impact factor: 11.528

2.  Acute transformation of chronic large granular lymphocyte leukemia associated with additional chromosome abnormality.

Authors:  Y Ohno; R Amakawa; S Fukuhara; C R Huang; H Kamesaki; H Amano; T Imanaka; Y Takahashi; Y Arita; T Uchiyama
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

3.  Malignant granular lymphoproliferation after Epstein-Barr virus infection: partial immunologic reconstitution with interleukin-2.

Authors:  F R Aronson; R A Dempsey; M Allegretta; J André-Schwartz; P A Poldre; C D Hillyer; D R Parkinson; R A Rudders; R S Schwartz; J W Mier
Journal:  Am J Hematol       Date:  1987-08       Impact factor: 10.047

4.  Molecular analysis of T cell receptor and CD3 genes in CD3- large granular lymphocytes (LGLs): evidence for the existence of CD3- LGLs committed to the T cell lineage.

Authors:  J Hara; K Yumura-Yagi; S Tagawa; S Ishihara; A Tawa; T Ninomiya; H Wakiguchi; C Shimazaki; T Kitani; K Kawa-Ha
Journal:  Leukemia       Date:  1990-08       Impact factor: 11.528

5.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.

Authors:  K Kawa-Ha; S Ishihara; T Ninomiya; K Yumura-Yagi; J Hara; F Murayama; A Tawa; K Hirai
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 6.  Severe chronic active Epstein-Barr virus infection syndrome.

Authors:  M Okano; S Matsumoto; T Osato; Y Sakiyama; G M Thiele; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions.

Authors:  G Semenzato; F Pandolfi; T Chisesi; G De Rossi; G Pizzolo; R Zambello; L Trentin; C Agostini; E Dini; M Vespignani
Journal:  Cancer       Date:  1987-12-15       Impact factor: 6.860

8.  Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders.

Authors:  K Oshimi; O Yamada; T Kaneko; S Nishinarita; Y Iizuka; A Urabe; T Inamori; S Asano; S Takahashi; M Hattori
Journal:  Leukemia       Date:  1993-06       Impact factor: 11.528

  8 in total
  1 in total

1.  Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.

Authors:  Michiko K Oyoshi; Hiroshi Nagata; Nobuhiro Kimura; Yu Zhang; Ayako Demachi; Toshiro Hara; Hirokazu Kanegane; Yoshinobu Matsuo; Tomohiro Yamaguchi; Tomohiro Morio; Atsuyoshi Hirano; Norio Shimizu; Kohtaro Yamamoto
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.